Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Nelipepimut-S Plus GM-CSF Vaccine

Known as: NeuVax Plus GM-CSF, Nelipepimut-S Plus Sargramostim, HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF 
A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Purpose: In phase I/II studies, nelipepimut-S (NP-S) plus GM-CSF vaccine was well tolerated and effectively raised HER2-specific… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2019
2019
The development of HER2-targeted therapy has decreased recurrence rates and improved survival, transforming the natural history… Expand
2016
2016
E75 (nelipepimut-S) is an immunogenic peptide derived from the HER2 protein. When combined with the immunoadjuvant granulocyte… Expand
  • figure 1
2016
2016
Purpose: E75, a peptide derived from the Her2/neu protein, is the most clinically advanced vaccine approach against breast cancer… Expand
  • figure 1
  • figure 4
  • figure 5
2016
2016
1001Background: The role of capecitabine (X) in the adjuvant treatment of BC is not established, and few long-term survival data… Expand
2015
2015
Background: In an adjuvant phase II trial, the HER2-derived nelipepimut-S (E75) + GM-CSF vaccine (Neuvax) has been shown to… Expand
Highly Cited
2014
Highly Cited
2014
BACKGROUND E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Review
2014
Review
2014
Nelipepimut-S (formerly known as E75) is an immunogenic peptide from the HER2 protein that is highly expressed in breast cancer… Expand
  • table 1
  • table 2
  • table 2
  • figure 1
  • figure 2
2013
2013
TPS3126 Background: We completed phase I/II clinical trials with NeuVax (nelipepimut-S), a HLA-A2/A3-restricted, HER2-derived… Expand